Atherosclerotic peripheral arterial disease (PAD) is a common disorder usually associated with silent or symptomatic arterial disease elsewhere in the circulation and a cluster of cardiovascular risk factors inducing atheroma progression and/or thrombotic complications. Because of these strong clinical associations, especially with coronary heart disease, the ankle-brachial pressure index (ABPI) is of prognostic significance. The clinical management of IC should include relief of symptoms combined with prevention of secondary cardiovascular complications, e.g. acute thrombotic events causing limb-or life-threatening ischaemia, which are often due to atherosclerotic plaque rupture leading to thrombotic vessel occlusion. Many patients with PAD do not receive an optimum package of secondary prevention, tailored to include maximum cholesterol reduction, BP and glycaemic control, ACE inhibition and single or combination anti-platelet therapy. This review considers recent information from large secondary prevention trials, e.g. the PAD subgroups within the HOPE, CAPRIE and statin studies. Slowing progression of atherosclerosis, and inducing stabilisation and regression of atheromatous plaques, is now feasible using long-term combination drug therapy. The phrase ''conservative therapy'', popular among vascular surgeons, implies a passive minimal-intervention strategy of surveillance and lifestyle advice; such terminology is perhaps no longer appropriate since considerable improvements in survival are likely to accrue if all patients with PAD, especially those with low ABPI, receive vigorous, titrated medical therapies, tailored to individual patients, as part of an evidence-based secondary prevention regime. Medical and surgical therapies for patients with inmay be indicated for relief of angina (e.g. when maxtermittent claudication (IC) have two separate but imal medical therapy fails) and/or prolongation of life complementary objectives: (1) symptom relief, i.e. imexpectancy (e.g. when there is triple vessel disease and proved walking distance and quality of life, and (2) impaired left ventricular function). 2 Similarly, medical prevention of secondary vascular complications, espetherapies such as aspirin have no effect on arterial cially plaque rupture leading to acute thrombotic symptoms, either angina or intermittent claudication, events that may be limb-threatening and/or life-threatbut antiplatelet therapy reduces the risk of secondary ening. Survival is related to the severity of peripheral thrombotic complications in the heart, brain and lower arterial disease (Fig. 1 ), 1 and different treatment stratlimb, which in turn prolongs survival when used as egies for IC (both medical and surgical) have variable secondary prevention. effects on each of these therapeutic goals (Fig. 2) . For
Introduction
survival, whereas for the corresponding disorder in the
Clinical Trials of Secondary Prevention

Application to patients with symptomatic PAD
Because the presence of IC signifies an increased risk of mortality, both from lower limb vascular complications (e.g. acute limb ischaemia, ulceration and gangrene) and non-limb vascular complications (e.g. acute myocardial infarction, stroke or sudden death), it is essential that patients with IC are given appropriate secondary prevention. Unfortunately, most of the evi- Fig. 1 . ABPI is a prognostic marker. Patient survival according to dence pertaining to this patient population has been ABPI, reflecting the strong association with silent or symptomatic extrapolated from large secondary prevention studies arterial disease in the heart and brain. Adapted from [1] .
undertaken primarily in patients with symptoms of coronary heart disease (CHD), some of whom also had PAD, but in practice all patients with clinical evidence of atherosclerosis -irrespective of whether the earliest symptoms of arterial stenosis localise to the heart, brain or legs -merit a package of secondary prevention treatments (Fig. 2) .
Smoking cessation
Cigarette smoking is the single most powerful risk factor associated with the aetiology and clinical progression of PAD. Among patients with IC, continued smoking is clearly associated with a greater likelihood of developing disabling claudication, limb-threatening 3, 4 In addition, patency rates and survival are should be combined with separate treatments that provide secondary prevention, ie evidence-based interventions that reduce the much lower among patients who smoke following a risk of limb-threatening or life-threatening thrombotic comrevascularisation procedure. 5 plications.
The increased cancer risk from smoking and the adverse effects on lung function persist for many years after a long-term smoker gives up cigarettes, but the excess risk of cardiovascular disease (i.e. death and ischaemia, acute myocardial ischaemia or sudden death. The term ''conservative therapy'', often used by nonfatal myocardial infarction) diminishes relatively quickly after smoking cessation, e.g. within 2-4 years. 6 vascular surgeons, is perhaps no longer appropriate for patients with IC because it implies a clinical man-Thus, patients with IC can be reassured that the vascular benefits of smoking cessation accrue almost im-agement based largely on passive surveillance and exercise, without surgical or intensive medical inter-mediately, even though the carcinogenic risk lingers on for at least another decade. This justifies a more vention. This is particularly inappropriate now that randomised controlled trials have demonstrated the intensive, evidence-based approach to smoking cessation in PAD patients, making use of treatments that efficacy and safety of a range of medical therapies for prolongation of survival among patients with ath-have been shown to relieve symptoms of nicotine withdrawal and improve quit rates among motivated erosclerotic vascular disease, whether or not this disease manifests initially as cardiac, peripheral or but nicotine-dependent smokers.
Strategies to help patients quit smoking should go cerebral symptoms. The purpose of this review is to provide an update on the evidence behind effective beyond simple advice and retribution. Because nicotine is a drug of dependence (it is the other con-secondary prevention that improves outcome (but not exercise-induced symptoms) in this high-risk patient stituents of cigarettes that promote atheroma), spontaneous quit rates are low even among patients group.
5.0
Inhaled: who want to give-up (<5% per year). Psychological shown that aspirin, either as monotherapy or in combination with dipyridamole, delays the progression of counselling and support improves cessation rates modestablished PAD, as assessed by serial angiography, estly, but there have been over 50 randomised, placeboand decreases the need for surgical revasculariscontrolled trials (RCTs) using various forms of nicotine ation. 9, 10 Aspirin also improves patency rates following replacement therapy (NRT) showing that quit rates revascularisation. 11 The standard dose of aspirin for after 1 year are doubled among motivated patients secondary prevention is usually 75-150 mg daily; given active NRT and educational support. The higher doses of aspirin provide no clear therapeutic Cochrane database has undertaken a meta-analysis of advantage but the incidence of gastrointestinal side-RCTs of NRT and shown beyond doubt that this effects is much higher. For example, in the secondary approach is safe and effective ( Fig. 3) . 7 There has also prevention of transient ischaemic attacks, aspirin been a Cochrane meta-analysis of a smaller number 30 mg was no less effective than aspirin 283 mg, but of RCTs using an oral agent, the antidepressant buhad fewer complications. 12 propion, as a 2-month course of therapy to relieve
The CAPRIRE study 13 showed that, overall, the adnicotine withdrawal symptoms ( Fig. 3 ). 8 It too is effectvantages of clopidogrel over aspirin are modest (<9%), ive but the weight of evidence favours NRT as the but in the subgroup with PAD clopidogrel had a more preferred first-line option.
impressive effect ( Fig. 4 ). Thus, in patients with IC newer antiplatelet agents may be preferred instead of aspirin for secondary prevention, especially among Anti-platelet therapy and warfarin those patients who are intolerant or allergic to aspirin. More recent studies in patients with unstable angina Aspirin therapy, while having no effect on walking suggest that the benefits of clopidogrel and aspirin distance or symptom status, does seem to modify the are additive, 14 implying that combination anti-platelet therapy will become more widely established. Pre-clinical course of PAD. Large randomised trials have the 4S study with simvastatin 16 and the CARE study with pravastatin. 17 These drugs block the rate-limiting enzyme in endogenous cholesterol biosynthesis in the liver (HMG-CoA reductase); less than 20% of circulating cholesterol (as opposed to fat, i.e. triglycerides) is derived from the diet. Therapy with simvastatin 20-40 mg or pravastatin 40 mg at night (most endogenous cholesterol biosynthesis occurs overnight), among patients with symptomatic CHD, reduced circulating cholesterol levels, on average, by 32%, with 30-40% reductions in fatal and non-fatal CHD Fig. 4 . In the CAPRIE study, 13 patients with PAD seem to obtain an events. 16, 17 Stroke risk was also reduced in both the 4S even greater benefit with clopidogrel (relative to aspirin) compared and CARE trials (20% reduction), suggesting that the with overall results for the entire study population. statin had extra-cardiac effects on the progression of atherosclerotic disease elsewhere in the circulation. vious combination strategies found only a marginal There seems to be a curvi-linear relationship beadvantage in adding dipyridamole to aspirin following tween cholesterol reduction and improved survival in TIA, but clopidogrel+aspirin seems to be significantly the 4S and CARE trials, i.e. a relationship of dimore effective, at least following an episode of unstable minishing return with ever-lower levels of cholesterol. angina (relative risk reduction was 20% vs aspirin Simvastatin and pravastatin are the only statins lialone for the composite primary endpoint of cardiocensed for secondary prevention; newer statins, withvascular death, myocardial infarction and stroke at 1 out mortality evidence, are licensed only for year 14 ).
''cholersterol reduction'', and the recent withdrawal Among patients with non-valvular atrial fibrillation of cerivastatin highlights the incomplete safety data-(AF) and IC, in whom there is a particular risk of base for newer statin drugs. acute embolic lower limb ischaemia and stroke, RCTs
Relatively little is published about the subgroups of and meta-analyses have clearly indicated that antipatients in these trials with PAD; only 4% of parcoagulation with warfarin (target INR 2.5-3.5) is ticipants in the 4S study had IC at baseline. 16 Neversuperior to aspirin, 15 although in elderly patients the theless, statin therapy is associated with plaque benefits of warfarin need to be carefully balanced on stabilisation and useful anti-inflammatory effects in an individual patient basis against the risk of lifethe vessel wall, and there is nothing to suggest that threatening bleeding complications, e.g. following a this pharmacological effect is confined to disease in simple fall or via gastrointestinal blood loss. AF affects the coronary arteries. 3-5% of the entire population over 60 years old, and A Cochrane meta-analysis of lipid-lowering therapy physicians routinely consider anticoagulation in in patients with PAD concluded that cholesterol repatients with AF under the age of 85 years, even in duction probably reduces mortality, 18 and there is evithe absence of thromboembolic symptoms, assuming dence that statins may alter the clinical course of PAD. the individual patient is otherwise mobile, reasonably For example, an analysis of the 4S study showed well and able to comply with warfarin therapy and that the incidence of ''new or worsening'' IC was monitoring. There is no evidence to support the routine significantly lower in CHD patients treated with simuse of warfarin (instead of aspirin or in addition to vastatin ( Fig. 5 ). 19 Thus, patients with symptomatic aspirin) for secondary prevention in IC patients in PAD and hypercholesterolaemia (total cholesterol sinus rhythm, although in some patients short-term >5 mmol/L), as well as those with overt CHD, should anticoagulation may be considered surgically benebe treated with a statin to achieve target LDL-choficial to avoid lower-limb complications post-oplesterol levels <3 mmol/L. The benefits apply equally eratively.
to men and women; those above and below 65 years of age; and especially patients with diabetes.
Lipid lowering therapy
Large randomised, placebo-controlled clinical trials in Blood pressure reduction patients with established CHD have clearly demonstrated major reductions in cardiac (and non-car-The Framingham epidemiological study provides observational evidence that patients with high blood diac) morbidity and mortality with statin therapy, e.g. control (BP <140/85 mmHg) among treated hypertensive patients are relatively low (<30%), even in specialist centres. This partly reflects the difficulty in lowering systolic BP, especially in the elderly, and it also reflects issues of tolerability and compliance with multiple antihypertensive therapies. Many patients develop postural symptoms or other drug-related side effects which limit the capacity to up-titrate medication in pursuit of target BP levels. Nevertheless, even modest BP reductions confer large clinical benefits and clinicians should strive for lower levels of treated BP It has been well established for a number of years that pathophysiologically with increased arterial stiffness, pressure-wave reflection and an increased systolic BP ACE inhibitors prolong survival and reduce symptoms and hospitalisation rates among patients with all load on the heart causing LV hypertrophy. Large placebo-controlled intervention studies over the last grades of heart failure, but the recent HOPE study showed that long-term treatment with ramipril (com-20 years, randomising patients at ever-lower levels of BP, have shown conclusively that even modest pared to placebo) as add-on to other cardiovascular therapies confers significant reductions in morbidity reductions in BP (eg 10/5 mmHg with monotherapy) translate into significant reductions in stroke (40%) and mortality among patients with CHD (and asymptomatic patients with diabetes plus one other and CHD (16%) mortality, and total cardiovascular mortality (30%). 21 More recently, the Hypertension risk factor) who do not have left ventricular (LV) dysfunction. 24 Some 9541 patients were randomised to Optimal Treatment (HOT) trial showed that, among treated hypertensives, aiming for lower target BP levels ramipril 10 mg or matching placebo in 19 countries for a mean follow-up period of 4-6 years. The primary (<80 mmHg diastolic) achieves maximum cardiovascular protection. 22 Even non-hypertensive patients endpoint of combined cardiovascular death, MI and stroke was reduced by 22% (p<0.000002); and all-treated with BP-lowering therapy, e.g. following a stroke, also benefit from added secondary prevention. 23 cause mortality was 17% lower (p<0.0035). Secondary endpoints included significantly fewer ramipril-Thus, the modern definition of hypertension (''that level of BP above which treatment does more good treated patients needing a revascularisation procedure (cardiac or peripheral) (relative risk reduction 12%, than harm'') is steadily reaching lower thresholds of BP that were previously regarded as within the ''normal'' p<0.0015). Vitamin E, which was also evaluated in the HOPE trial (vs placebo) using a 2×2 factorial design, range. The intervention trials in hypertension have generally not included lower-limb endpoints, but it is had no significant effects.
A subgroup analysis of 4046 subjects with PAD in clear that high BP is a risk factor for IC and that ISH in particular (commonly associated with PAD) the HOPE trial suggests that this particular subgroup gains even more benefit from ramipril compared with predisposes to arterial stiffness, cardiac hypertrophy and progression of the atherosclerotic process. Tight those without PAD (Fig. 7) .
This very large and well conducted clinical trial BP control (target BP <140/85 mmHg) is therefore an essential aspect of management in elderly patients provides persuasive evidence that effectively any patient with symptomatic atherosclerotic disease (or with IC, and this will inevitably require combination drug therapy. Diuretics are ideal first-line treatments asymptomatic diabetics with one other risk factor),
including those with IC, should be treated with an for elderly patients with ISH. The risk of underlying renovascular disease should always be considered in ACE inhibitor as part of secondary prevention, irrespective of other background medical therapies and patients with PAD, treatment-resistant hypertension and mild renal impairment, especially smokers. even if they are normotensive with normal LV function.
Because patients in the HOPE study were already Success rates in achieving the current targets for BP responding reductions in all major vascular events were 29% and 24% (p<0.001). 23 Fig. 7 . The results of the HOPE study 24 according to whether patients had PAD or not at baseline. The benefits of ramipril 10 mg/d were Thus, the significance of the HOPE study (a single at least as good (if not better) in the PAD subgroup. but very large, well conducted trial) would suggest that all patients with symptomatic PAD, where possible, should receive an ACE inhibitor in addition to their other cardiovascular therapies. ACE inhibitors are contreated with various BP-lowering and other cardiotra-indicated in patients with bilateral renal artery vascular therapies, e.g. anti-anginals, baseline BP prior stenosis (RAS), or unilateral RAS in a single functo the addition of ramipril or placebo was relatively tioning kidney. They should otherwise be used with good (139/79 mmHg). Only 46% of study participants caution in the presence of renal impairment and if had a prior diagnosis of hypertension. The net antithere is a suspicion of possible RAS. Because the hypertensive effect of ramipril was only 2/3 mmHg, incidence of RAS is quite high in the PAD population, which seems unlikely to explain the considerable beit is therefore essential to use a low starting dose and nefits in terms of prolonged survival. Thus, it seems to check the serum electrolytes 1 week and 1 month likely that ACE inhibitors confer protective effects on after starting or increasing ACE inhibitor therapy. In the atherosclerotic process that are clinically important, the HOPE trial (and other pragmatic ACE inhibitor e.g. improved endothelial function, over and above studies), where patients were not screened in detail to the benefits attributable to BP reduction. exclude RAS, the actual incidence of complications The notion of non-BP-mediated benefits of ACE inhibitors in secondary prevention is also supported (e.g. renal failure) was surprisingly low. 
Glycaemic control in diabetes
Experimental studies of potential new secondary prevention therapies are focusing on:
Patients with diabetes tend to have more severe, often distal and diffuse, multivessel PAD that is less amen-• reversing endothelial dysfunction (an early hallmark of arterial disease) by restoring normal vasorelaxation, able to revascularisation, and restenosis in diabetics is antithrombotic mechanisms and inter-cellular adhesion; a particular problem following angioplasty. 25 The risk • plaque stabilisation and regression via blocking inflammatory of lower limb ulceration is exacerbated by microvessel processes;
• prevention of neointimal hyperplasia and restenosis following disease and neuropathy, as well as PAD, and amballoon injury during angioplasty; putation rates among diabetics (mainly distal am-• changes in intima-media thickness to reflect slowing of the putations) are 40-fold higher than in age-matched atherosclerotic progression;
• use of crosslink breakers to inhibit advanced glycosylation nondiabetic controls. 26 (AGE) processes in the mediation of vascular ageing and Type 2 diabetes is very much a clinical syndrome in vascular stiffness.
which hyperglycaemia is only one facet; other features include insulin resistance, hypertension, obesity and dyslipidaemia. The major benefit of tight glycaemic control is in the prevention of microangiopathy (ret-Therapeutic Targets for New Vascular Diseaseinopathy, nephropathy, neuropathy), whereas tight BP modifying Agents: the Future of Secondary control has a much greater impact on macrovascular Prevention complications and death rates. For example, in the UK Prospective Diabetes Study (UKPDS), every 10 mmHg RCTs of sufficient size and duration to assess treatment reduction in systolic BP was associated with a 12% effects on morbidity and mortality are the ultimate reduction in any diabetes-related complication; 15% benchmark standard for establishing the role of a new reduction in death related to diabetes; 11% reduction drug in long-term secondary prevention. But advances in MI; and 13% reduction in microvascular comin the understanding of how atherosclerotic disease plications. 27 Thus, BP reduction ameliorates microdevelops and progresses has identified several target vessel complications and (unlike tight glycaemic conmechanisms for new agents aimed at achieving detrol) reduces diabetes-related deaths.
layed progression, plaque stabilisation and even re-Increasing Hb A1c is still a risk factor for large vessel gression of arterial disease (Table 1) . complications, 28 but the principal benefits of glucose For example, recent evidence has shown using ultrareduction are in microvessel protection and, for the sound that ramipril treatment in the HOPE study lower limb, prevention of neuropathy and secondary retards the progression of atherosclerosis, as demcomplications such as ulceration and infection. For onstrated by the annual increase in carotid intimaevery 1% increase in Hb A1c there is a 28% increased media thickness; 29 adjuvant anti-platelet therapy risk of death, independent of age, BP, serum cholesterol (clopidogrel+aspirin) provides improved outcomes and smoking status. 28 More importantly, however, over following percutaneous angioplasty; 30 and statins im-80% of the population excess mortality risk associated prove endothelial function, independent of their lipidwith HbA1c occurs in men with HbA1c concentrations lowering effects. 31 In addition, there is recent evidence of 5-6.9% (which is the majority of the population and that cilostazol (a symptom relieving drug in IC) inhibits includes people who, by definition, are not diabetic). 28 neointimal hyperplasia and restores endothelial function following balloon injury, 32 and increases vascular endothelial growth factor (VEGF) mediated collateral vessel formation. 33
Multiplicative interaction of risk factors
Conclusions Most patients with IC have more than one modifiable risk factor, and it is important to remember that risk IC is a common and disabling symptom associated with increased cardiovascular mortality due to acute factors have greater-than-additive effects on overall risk (Fig. 6) . 20 Thus, a clinical strategy of multiple thrombotic complications superimposed on a ruptured plaque causing limb-threatening or life-threatening risk factor intervention is likely to yield significantly greater benefits than incomplete treatment with tar-ischaemia. The overall management of patients with IC should include treatments (medical, surgical and geted secondary prevention of single risk factors. 
